Literature DB >> 11571505

Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation.

R Martino1, M D Caballero, C Canals, J San Miguel, J Sierra, M Rovira, C Solano, J Bargay, J Pérez-Simon, A León, J Sarrá, S Brunet, R de la Cámara.   

Abstract

We compared the occurrence of severe infections following 71 reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell transplants (PBSCT) and 123 standard myeloablative PBSCT (MINI and STAND groups, respectively) from HLA-identical siblings. The probability of 1-year infection-related mortality (IRM) was 19% in the STAND group and 10% in the MINI group (log-rank, P = 0.3). On multivariate analysis the only significant variable associated with a higher risk of IRM was the development of moderate-to-severe GVHD (P = 0.005). The probability of developing CMV infection was 39% in the STAND group and 21% in the MINI group (P = 0.03) (43% and 21%, respectively, in seropositive donor/recipient pairs, P = 0.01), and the probability of developing CMV disease was 9.5% and 1%, respectively (P = 0.05) (11% and 1%, respectively, in seropositive donor/recipient pairs, P = 0.03). Multivariate analysis of CMV infection identified four variables associated with a higher risk: CMV positive serostatus (P = 0.05), STAND transplant group (P = 0.02), the development of moderate-to-severe GVHD (P < 0.001) and a dose of CD34(+) cells infused below 6 x 10(6)/kg (P = 0.01). Invasive fungal infections and pneumonias of unknown origin did not differ between groups, and neither did other severe non-CMV viral infections and bacterial infections. Our results suggest that RIC allogeneic PBSCT may decrease the risk of dying from an opportunistic infection and reduces the occurrence of CMV infection and disease. Overall, the development of GVHD (acute or chronic) is an important risk factor for these complications. Other infections continue to pose a significant threat to recipients of RIC allografts, stressing that prophylactic and supportive measures are an important aspect in their care.

Entities:  

Mesh:

Year:  2001        PMID: 11571505     DOI: 10.1038/sj.bmt.1703150

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

Review 1.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Rodrigo Martino; Rocio Parody; Takahiro Fukuda; Johan Maertens; Koen Theunissen; Aloysius Ho; Ghulam J Mufti; Nicolaus Kroger; Arnold R Zander; Dominik Heim; Monika Paluszewska; Dominik Selleslag; Katerina Steinerova; Per Ljungman; Simone Cesaro; Anna Nihtinen; Catherine Cordonnier; Lourdes Vazquez; Monica López-Duarte; Javier Lopez; Rafael Cabrera; Montserrat Rovira; Stefan Neuburger; Oliver Cornely; Ann E Hunter; Kieren A Marr; Hans Jürgen Dornbusch; Hermann Einsele
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

3.  Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients.

Authors:  Steven A Pergam; Hu Xie; Ravinder Sandhu; Margaret Pollack; Jeremy Smith; Terry Stevens-Ayers; Valeria Ilieva; Louise E Kimball; Meei-Li Huang; Tracy S Hayes; Lawrence Corey; Michael J Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-03       Impact factor: 5.742

4.  Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 5.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

6.  Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR.

Authors:  Renata M B Peres; Cláudia R C Costa; Paula D Andrade; Sandra H A Bonon; Dulcinéia M Albuquerque; Cristiane de Oliveira; Afonso C Vigorito; Francisco J P Aranha; Cármino A de Souza; Sandra C B Costa
Journal:  BMC Infect Dis       Date:  2010-06-01       Impact factor: 3.090

7.  Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.

Authors:  David I Marks; Antonio Pagliuca; Christopher C Kibbler; Axel Glasmacher; Claus-Peter Heussel; Michal Kantecki; Paul J S Miller; Patricia Ribaud; Haran T Schlamm; Carlos Solano; Gordon Cook
Journal:  Br J Haematol       Date:  2011-08-22       Impact factor: 6.998

8.  Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation.

Authors:  Hwa Kyung Byun; Hong In Yoon; Jaeho Cho; Hyun Ju Kim; Yoo Hong Min; Chuhl Joo Lyu; June-Won Cheong; Jin Seok Kim; Hyo Sun Kim; Soo-Jeong Kim; Andrew Jihoon Yang; Byung Min Lee; Won Hee Lee; Joongyo Lee; Ki Jung Ahn; Chang-Ok Suh
Journal:  Radiat Oncol J       Date:  2017-09-29

9.  High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation.

Authors:  R Nakamura; K Cortez; S Solomon; M Battiwalla; V J Gill; N Hensel; R Childs; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

10.  Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT.

Authors:  R Martino; J L Piñana; R Parody; D Valcarcel; A Sureda; S Brunet; J Briones; J Delgado; F Sánchez; N Rabella; J Sierra
Journal:  Bone Marrow Transplant       Date:  2009-04-27       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.